AKT1 and non-small cell lung carcinoma: A trabectedin-mimic derivative of RT, 5-O-acetyl-renieramycin T (O-acetyl RT), could significantly deplete Akt and reverse CSC-associated cisplatin resistance in non-small-cell lung carcinoma (NSCLC) [24].